Jim Mitchell

Benuvia Therapeutics Inc. is focused on financing and developing low-risk assets with high clinical value to improve the quality of life for patients with rare and underserved diseases. We have a broad pipeline of clinical stage product candidates targeting rare and underserved diseases. Our pipeline is based on nearly a decade of clinical research across a dozen clinical studies. We seek partners to support the future development of these candidate assets through the 505(b)2 pathway. Further information is available at www.benuvia.com.